Fibromyalgia Trial, Recruiting NCT06320262 Sponsor: Rasmia Elgohary Condition: Fibromyalgia
Back to Fibromyalgia

Fibromyalgia Trial, Recruiting

NCT06320262
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 55 years old
  • You are female
  • You have been diagnosed with primary fibromyalgia based on the 2016 American College of Rheumatology guidelines
  • You have a moderate-to-high level of pain, scoring 45 or above on a standard 100-point pain scale
  • You have not taken certain medications — including muscle relaxants, antidepressants, anti-seizure drugs, steroids, benzodiazepines (such as sedatives), or tramadol — in the past year

Who may not be able to join:

  • You have been diagnosed with a rheumatic, cancer-related, metabolic, blood, or neurological condition
  • You have a bleeding disorder or take blood-thinning medications
  • You have taken muscle relaxants, antidepressants, anti-seizure drugs, steroids, benzodiazepines, or tramadol in the past year, or are currently taking any of them
  • Your body mass index (BMI) is 18 or below, or 35 or above (confirm with trial site if unsure of your BMI)
  • You are currently pregnant or breastfeeding
  • You have been diagnosed with severe anemia (very low red blood cell levels)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Mohamed Yousef, Professor, Kasr Alainy School of Medicine, Cairo University, Egypt

Phone: 01111370118

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Rasmia Elgohary
Registry
ClinicalTrials.gov
Start date
26 December 2024
Est. completion
1 October 2025

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Change from baseline brain MRS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov